# Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

> **NCT04740190** · PHASE2 · COMPLETED · sponsor: **The University of Hong Kong** · enrollment: 33 (actual)

## Conditions studied

- Recurrent Glioma
- Recurrent Glioblastoma
- Poly ADP Ribose Polymerase (PARP) Inhibitor
- PTEN Gene Inactivation
- IDH Mutation

## Interventions

- **DRUG:** Talazoparib

## Key facts

- **NCT ID:** NCT04740190
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-01
- **Primary completion:** 2023-12-14
- **Final completion:** 2023-12-14
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04740190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04740190, "Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04740190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*